We seek to improve understanding of the epidemiology, treatments, and impact of rare dermatologic disorders.
Much of our work has focused on pyoderma gangrenosum (PG), an inflammatory neutrophilic disorder. Through a collaboration with colleagues at the University of Pennsylvania, we performed a multi-center evaluation of the epidemiology of PG, with an emphasis on the impact of age on patients presentation and recommended workup.
Inspired by our patients, we investigated the risk of developing PG after procedures in patients with a history of the disease, and evaluated the efficacy and safety of intravenous immunoglobulin and topical and systemic dapsone for this rare disorder.
We are proud to be part of the multi-institutional Dermatology Research Consortium, which has created a network of multiple institutions to study rare dermatology conditions including necrobiotic xanthogranuloma and necrobiosis lipodica.
Xia FD, Liu K, Lockwood S, et al. Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum-A retrospective analysis. Journal of the American Academy of Dermatology. 2018;78(2):310-314.e311.
Song H, Lahood N, Mostaghimi A. Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series. The British journal of dermatology. 2018;178(2):363-368.
Pinard J, Chiang DY, Mostaghimi A, Granter SR, Merola JF, Barkoudah E. Wounds That Would Not Heal: Pyoderma Gangrenosum. The American journal of medicine. 2018;131(4):377-379.
Mostaghimi A, Joyce C. Reply to: “Re-evaluating pyoderma gangrenosum patients for Behcet disease before initiating any invasive procedures is essential”. Journal of the American Academy of Dermatology. 2018;79(2):e33.
Lockwood SJ, Li DG, Butler D, Tsiaras W, Joyce C, Mostaghimi A. The validity of the diagnostic code for pyoderma gangrenosum in an electronic database. The British journal of dermatology. 2018;179(1):216-217.
Li DG, Din RS, Tsiaras WG, Mostaghimi A. Evaluating the Efficacy of Topical Dapsone Treatment for Pyoderma Gangrenosum: A Retrospective Case Series. Journal of cutaneous medicine and surgery. 2018;22(6):650-651.
Din RS, Tsiaras WG, Mostaghimi A. Two cases of maggot debridement therapy in pyoderma gangrenosum. JAAD case reports. 2018;4(10):1027-1029.
Din RS, Tsiaras WG, Li DG, Mostaghimi A. Efficacy of Systemic Dapsone Treatment for Pyoderma Gangrenosum: A Retrospective Review. Journal of drugs in dermatology : JDD. 2018;17(10):1058-1060.
Ashchyan HJ, Butler DC, Nelson CA, et al. The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum. JAMA dermatology. 2018;154(4):409-413.
Department of Dermatology
Brigham and Women’s Hospital
Boston, MA, 02215